<DOC>
	<DOCNO>NCT02644759</DOCNO>
	<brief_summary>Type 1 diabetes mellitus ( T1DM ) chronic , autoimmune condition involve progressive destruction pancreatic β-cells , eventually result loss insulin production secretion . Hence , effective treatment T1DM focus control anti-β-cell autoimmunity , combine regeneration lose pancreatic β-cell population , minimal risk patient . This phase I II clinical trial treatment patient confirm diagnosis T1DM least 12 month prior enrolment trial . This study aim determine combine effect autologous stem cell transplantation immunomodulation , regeneration lose β-cells halt immune attack pancreatic β-cells , respectively .</brief_summary>
	<brief_title>Transplantation Autologous Stem Cells Treatment Type 1 Diabetes Mellitus</brief_title>
	<detailed_description>Patients T1DM depend administration exogenous insulin survival control long-term complication . The best-established treatment constrict control blood glucose accomplished regular daily injection constant subcutaneous infusion insulin intensive insulin therapy . Although insulin therapy advance immensely , even modern technology allow maintenance normal glucose level . This prospective pilot study intend treat patient T1DM least one year confirm diagnosis . This study encompass two-arm approach ; first arm compose clinical-grade purification autologous , leukapheresis-derived , Cluster differentiation 34+ 133+ stem cell ( accomplished utilisation CliniMACS System approve clinical-grade Microbeads accessory ) , transplantation purify ell population pancreatic artery capillary via interventional radiology technique ; second arm aim halt immune attack pancreatic β-cells immunomodulation , compose incubation patient 's leukapheresis cord blood-derived mesenchymal stem cell 3-6 hour , return patient 's white blood cell back patient via intravenous injection . Patients first mobilise 10 ug/Kg Granulocyte-Colony Stimulating Factor ( GCSF ) five day , Mononuclear Cells collect patient via leukapheresis .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Immune System Diseases</mesh_term>
	<mesh_term>Glucose Metabolism Disorders</mesh_term>
	<mesh_term>Endocrine System Diseases</mesh_term>
	<criteria>Confirmed Type 1 diabetes mellitus diagnose least 12 month prior execution protocol . Pregnancy Severe psychiatric disorder Severe organic impairment ( renal , hepatic , cardiac , pulmonary ) Active infectious disease Previous present neoplastic disease Any serious complication due poor control diabetes , include : low limb ischemia , kidney failure , liver failure , vision impairment , peripheral neuropathy , poor circulation .</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Stem Cells</keyword>
	<keyword>Transplantation</keyword>
	<keyword>Immunomodulation</keyword>
	<keyword>CD34</keyword>
	<keyword>CD133</keyword>
	<keyword>ClinicMACS</keyword>
</DOC>